Overview
Hrishikesh Chakraborty, is a Professor in the Department of Biostatistics and Bioinformatics at Duke University and affiliated with the Duke Clinical Research Institute. He is an internationally experienced biostatistician whose work integrates statistical methodology, clinical trial design, data coordinating center leadership, and collaborative biomedical research. Over more than 25+ years of independent and collaborative research, he has contributed to more than 20+ clinical trials and authored more than 100 peer-reviewed publications. His research spans pragmatic and cluster-randomized trials, HIV/AIDS, maternal and child health, survival analysis, genomic medicine, dietary metabolomic biomarker discoveries, cardiovascular and kidney disease, pulmonary hypertension, pain management, and other areas of public health and clinical research.
Dr. Chakraborty has served as principal investigator for multiple data coordinating centers and has provided statistical leadership for large, multisite, federally funded research initiatives. His work encompasses the full research lifecycle, including study design, protocol development, sample-size and power calculations, data management and harmonization, study monitoring, statistical analysis, interpretation, and dissemination. His multidisciplinary background in statistics, biostatistics, and sociology supports a collaborative approach that connects rigorous quantitative methods with consequential clinical and public health questions.
Current Duke Appointments & Affiliations
Recent Scholarly Works
SOCIODEMOGRAPHIC AND CLINICAL FACTORS ASSOCIATED WITH POST- SURGICAL OPIOID MISUSE AND PERSISTENCE: SECONDARY ANALYSIS OF THE ADOPT PGX ACUTE PAIN TRIAL.
Conference CLINICAL PHARMACOLOGY & THERAPEUTICS · September 2026 Link to item CiteASSOCIATIONS BETWEEN CYP2D6 PHENOTYPE AND POST- OPERATIVE OPIOID PERSISTENCE AND MISUSE
Conference CLINICAL PHARMACOLOGY & THERAPEUTICS · September 2026 Link to item CiteTramadol Co-Administration with Oxycodone or Hydrocodone Increases Opioid Burden without Improving Postoperative Pain Control.
Journal article Clin Pharmacol Ther · August 17, 2026 Tramadol is frequently co-prescribed with oxycodone or hydrocodone after surgery under the assumption that its dual mechanism of action provides an opioid-sparing benefit. However, evidence supporting this practice is limited and inconsistent. We conducted ... Full text Link to item CiteRecent Grants
AI-driven Multimodal Model for PrEP Candidacy Assessment in Women (AiM-PrEP)
ResearchCo Investigator · Awarded by National Institutes of Health · 2026 - 20312/2 Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFPEF)
ResearchPrincipal Investigator · Awarded by National Heart, Lung, and Blood Institute · 2024 - 2028A randomized controlled trial of a novel, evidence-based algorithm for managing lower respiratory tract infection in a resource-limited setting
ResearchCollaborator · Awarded by National Institute of Allergy and Infectious Diseases · 2022 - 2027View All Grants